ClinicalTrials.gg
CompletedNCT01610791Updated Jul 10, 2014Results posted

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)

A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 8 sites in Morocco. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-10.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
121
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
46th of 110
121 · median 97
Started
2010
with 13 others
Phase 3
65 of 110
none open now
Registered
59th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 46th largest by enrollment, is one of 14 that started in 2010, is one of 65 in phase 3, and was the 59th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This open label, single arm study will assess the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Actemra at a dose of 8 mg/kg intravenously every 4 weeks for 24 weeks (6 infusions).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Moderate to severe active rheumatoid arthritis (DAS28 > 3.2 at screening)
  • Inadequate response to DMARDs
  • Body weight \< 150 kg

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months of enrollment
  • Rheumatic disease other than RA
  • American College of Rheumatology (ACR) functional class IV
  • Prior history of or current inflammatory joint disease other than RA
  • Previous treatment with any biologic drug that is used in the treatment of RA
  • Intraarticular or parenteral within 6 weeks prior to baseline
  • Pregnant or lactating women
  • Active current or history of recurrent infection, active TB within the previous 3 years, infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Single Arm

    Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 mg/kg iv every 4 weeks, total of 6 infusions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events

    Percentage of participants with adverse events (AEs), serious adverse events (SAEs), severe AEs, AEs leading to withdrawal, AEs leading to death, and treatment-related AEs.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcomes

  1. Percentage of Participants With All-Cause Discontinuation of Tocilizumab by Study Visit

    Percentage of participants discontinuing study treatment for any reason at every visit; causes of discontinuation in the summary included AEs, deaths, lost to follo-wup, AE and investigator decision and 'not determined'.

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  2. Change From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) to Highest Value

    The difference between baseline and highest values until Week 24 of ALT and AST. The values are measures as international units per liter (UI/L). The change was calculated as the value (highest) at a later timepoint up to Week 24, minus the value at Baseline.

    Time frame: Baseline through Week 24

  3. Change From Baseline Low-Density Lipoprotein (LDL) and Total Cholesterol (TC) to Highest Values

    Levels of LDL and TC were measured in milligrams/deciliter (mg/dL). Change in LDL and TC were calculated as the value (highest) through Week 24, minus the value at Baseline.

    Time frame: Baseline through Week 24

  4. Percentage of Participants With Lipid Elevations by Study Visit

    Lipid panel assessed included TC, triglycerides, high-density lipoprotein (HDL), and LDL. Elevations were categorized as follows: LDL cholesterol: Optimal equals (=) less than (\<)100 mg/dL, Near optimal=100-129 mg/dL, Borderline high 130-159 mg/dL, High 160-189 mg/dL, Very High ≥190 mg/dL; Total cholesterol: Desirable \<200 mg/dL, Borderline high 200-239 mg/dL, High ≥240 mg/dL; HDL cholesterol: Low \<40 mg/dL, High ≥60 mg/dL; Triglycerides: Normal \<150 mg/dL, Borderline high 150-199 mg/dL, High 200-499 mg/dL, and Very high ≥500 mg/dL.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  5. Disease Activity Score Based on 28-Joint Count (DAS28)

    DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR; in millimeters per hour \[mm/hour\]) and global health assessment (participant-rated global assessment of disease activity using 10-mm visual analog assessment \[VAS\]); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 less than or equal to (≤3.2) = low disease activity, DAS28 greater than (\>)3.2 to less than or equal to (≤) 5.1=moderate to high disease activity; DAS28 \>5.1=high disease activity.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  6. Percentage of Participants by DAS28 Response Category

    DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 =low disease activity, DAS28 \>3.2 to ≤5.1=moderate to high disease activity; DAS28 \>5.1=high disease activity.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  7. Percentage of Participants With a Clinically Meaningful Improvement in Disease Activity

    DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. A reduction in DAS28 of at least 1.2 units was considered a clinically meaningful improvement.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  8. Time to Achieve Clinically Meaningful Reduction in DAS28

    A clinically meaningful improvement in DAS28 was defined as a reduction of at least 1.2 units. Time to achieving clinically meanigful improvement was calculated as the number of days from the first infusion to the first achievement of reduction of 1.2 units in DAS28.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  9. Percentage of Participants Achieving Remission (DAS28 <2.6)

    DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Participants with a DAS28 score \<2.6 were considered to have achieved remission.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  10. Percentage of Participants With a Response Assessed Using American College of Rheumatology (ACR) Criteria

    The ACR response rates ACR20, ACR50, ACR70 are defined as ≥20%, ≥50%, ≥70% improvement, respectively, in: swollen joint count (SJC) (66 joints) and tender joint count (TJC) (68 joints) and 3 of the following 5 assessments: Patient assessment of pain (VAS); Patient global assessment of disease activity (VAS); Investigator global assessment of disease activity (VAS); and acute phase response (ESR or CRP)

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  11. Swollen and Tender Joint Counts

    The following 28 joints were assessed by the physician for swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). The following 28 joints were assessed by the physician for tenderness : metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). The change in SJC and TJC was determined as the difference in values from baseline at each visit.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  12. Health Assessment Questionnaire (HAQ)

    HAQ was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple-choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The change in HAQ was determined as the difference in values from baseline at each visit.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  13. Patient Global Assessment of Disease Activity (VAS)

    The participant's overall assessment of their current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no disease activity" (symptom free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity" (maximum arthritis disease activity). The change in Patient Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  14. Physician's Global Assessment of Disease Activity (VAS)

    The physician's assessment of the participant's current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity". The Physician's Global Assessment of Disease Activity was completed by the Efficacy Assessor who could or could not be a physician. The change in Physician's Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  15. Patient Assessment of of Pain (VAS)

    The participant's assessment of their current level of pain was displayed on a 100-mm horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no pain" and the right-hand extreme of the line (100 mm) was described as "unbearable pain". The change in participant's perception of pain was determined as the difference in values from baseline at each visit.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  16. C-Reactive Protein (CRP)

    CRP is an acute phase inflammatory marker. Levels of CRP increase with inflammation. The change in CRP was determined as the difference in values from baseline and at each visit.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  17. Erythrocyte Sedimentation Rate (ESR)

    ESR indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. The change in ESR was determined as the difference in values from baseline at each visit.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

07

Results

Posted Jul 10, 2014
Limitations and caveats
Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab 8 mg/kg
Started121
Completed100
Not completed21
Withdrew: Lost to follow-up7
Withdrew: Adverse event6
Withdrew: Physician decision1
Withdrew: Adverse event and investigator decision1
Withdrew: Death1
Withdrew: Not determined5

Outcome measures

SecondaryPercentage of Participants With All-Cause Discontinuation of Tocilizumab by Study Visit

Percentage of participants discontinuing study treatment for any reason at every visit; causes of discontinuation in the summary included AEs, deaths, lost to follo-wup, AE and investigator decision and 'not determined'.

Time frame:
Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With All-Cause Discontinuation of Tocilizumab by Study Visit
percentage of participantsTocilizumab 8 mg/kg
Week 43.3
Week 83.3
Week 122.5
Week 162.5
Week 202.5
Week 243.3
SecondaryChange From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) to Highest Value

The difference between baseline and highest values until Week 24 of ALT and AST. The values are measures as international units per liter (UI/L). The change was calculated as the value (highest) at a later timepoint up to Week 24, minus the value at Baseline.

Time frame:
Baseline through Week 24
Reported as:
Mean · UI/L
Change From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) to Highest Value
UI/LTocilizumab 8 mg/kg
ALT23.6 ± 34.7
AST15.8 ± 22.1
Statistical analysis
  • Tocilizumab 8 mg/kg · t-test, 2 sided · p = <0.001
  • Tocilizumab 8 mg/kg · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline Low-Density Lipoprotein (LDL) and Total Cholesterol (TC) to Highest Values

Levels of LDL and TC were measured in milligrams/deciliter (mg/dL). Change in LDL and TC were calculated as the value (highest) through Week 24, minus the value at Baseline.

Time frame:
Baseline through Week 24
Reported as:
Mean · mg/dL
Change From Baseline Low-Density Lipoprotein (LDL) and Total Cholesterol (TC) to Highest Values
mg/dLTocilizumab 8 mg/kg
Total cholesterol57.2 ± 78.1
LDL cholesterol108.6 ± 106.2
Statistical analysis
  • Tocilizumab 8 mg/kg · t-test, 2 sided · p = <0.001
  • Tocilizumab 8 mg/kg · t-test, 2 sided · p = <0.001
SecondaryPercentage of Participants With Lipid Elevations by Study Visit

Lipid panel assessed included TC, triglycerides, high-density lipoprotein (HDL), and LDL. Elevations were categorized as follows: LDL cholesterol: Optimal equals (=) less than (\<)100 mg/dL, Near optimal=100-129 mg/dL, Borderline high 130-159 mg/dL, High 160-189 mg/dL, Very High ≥190 mg/dL; Total cholesterol: Desirable \<200 mg/dL, Borderline high 200-239 mg/dL, High ≥240 mg/dL; HDL cholesterol: Low \<40 mg/dL, High ≥60 mg/dL; Triglycerides: Normal \<150 mg/dL, Borderline high 150-199 mg/dL, High 200-499 mg/dL, and Very high ≥500 mg/dL.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Lipid Elevations by Study Visit
percentage of participantsTocilizumab 8 mg/kg
LDL Cholesterol: Optimal, Baseline (n=120)53.3
LDL Cholesterol: Optimal, Week 4 (n=116)32.8
LDL Cholesterol: Optimal, Week 8 (n=112)42.9
LDL Cholesterol: Optimal, Week 12 (n=109)33.9
LDL Cholesterol: Optimal, Week 16 (n=106)18.9
LDL Cholesterol: Optimal, Week 20 (n=102)38.2
LDL Cholesterol: Optimal, Week 24 (n=98)28.6
LDL Cholesterol: Near Optimal, Baseline (n=120)30.8
LDL Cholesterol: Near Optimal, Week 4 (n=116)31.9
LDL Cholesterol: Near Optimal, Week 8 (n=112)22.3
LDL Cholesterol: Near Optimal, Week 12 (n=109)25.7
LDL Cholesterol: Near Optimal, Week 16 (n=106)17.9
LDL Cholesterol: Near Optimal, Week 20 (n=102)22.5
LDL Cholesterol: Near Optimal, Week 24 (n=98)27.6
LDL Cholesterol: Borderline High, Baseline (n=120)12.5
LDL Cholesterol: Borderline High, Week 4 (n=116)21.6
LDL Cholesterol: Borderline High Week 8 (n=112)23.2
LDL Cholesterol: Borderline High, Week 12 (n=109)20.2
LDL Cholesterol: Borderline High, Week 16 (n=106)15.1
LDL Cholesterol: Brderline High, Week 20 (n=102)25.5
LDL Cholesterol: Borderline High, Week 24 (n=98)29.6
LDL Cholesterol: High, Baseline (n=120)2.5
LDL Cholesterol: High, Week 4 (n=116)7.8
LDL Cholesterol: High, Week 8 (n=112)9.8
LDL Cholesterol: High, Week 12 (n=109)14.7
LDL Cholesterol: High, Week 16 (n=106)9.4
LDL Cholesterol: High, Week 20 (n=102)10.8
LDL Cholesterol: High, Week 24 (n=98)9.2
LDL Cholesterol: Very High, Baseline (n=120)0.8
LDL Cholesterol: Very High, Week 4 (n=116)6.0
LDL Cholesterol: Very High, Week 8 (n=112)1.8
LDL Cholesterol: Very High, Week 12 (n=109)5.5
LDL Cholesterol: Very High, Week 16 (n=106)38.7
LDL Cholesterol: Very High, Week 20 (n=102)2.9
LDL Cholesterol: Very High, Week 24 (n=98)5.1
TC: Desirable, Baseline (n=120)77.5
TC: Desirable, Week 4 (n=116)58.6
TC: Desirable, Week 8 (n=85)28.6
TC: Desirable, Week 12 (n=109)56.0
TC: Desirable, Week 16 (n=106)56.6
TC: Desirable, Week 20 (n=103)52.4
TC: Desirable, Week 24 (n=98)51.0
TC: Borderline High, Baseline (n=120)18.3
TC: Borderline High, Week 4 (n=116)25.0
TC: Borderline High, Week 8 (n=85)28.6
TC: Borderline High, Week 12 (n=109)23.9
TC: Borderline High, Week 16 (n=106)26.4
TC: Borderline High, Week 20 (n=103)28.2
TC: Borderline High, Week 24 (n=98)26.5
TC: High, Baseline (n=120)4.2
TC: High, Week 4 (n=116)16.4
TC: High, Week 8 (n=85)18.8
TC: High, Week 12 (n=109)20.2
TC: High, Week 16 (n=106)17.0
TC: High, Week 20 (n=103)19.4
TC: High, Week 24 (n=98)22.4
HDL Cholesterol: Low, Baseline (n=49)28.1
HDL Cholesterol: Low, Week 4 (n=47)12.9
HDL Cholesterol: Low, Week 8 (n=54)17.7
HDL Cholesterol: Low, Week 12 (n=42)11.0
HDL Cholesterol: Low, Week 16 (n=51)24.5
HDL Cholesterol: Low, Week 20 (n=52)22.3
HDL Cholesterol: Low, Week 24 (n=48)19.4
HDL Cholesterol: High, Baseline (n=49)12.4
HDL Cholesterol: High, Week 4 (n=47)27.6
HDL Cholesterol: High, Week 8 (n=54)30.1
HDL Cholesterol: High, Week 12 (n=42)27.5
HDL Cholesterol: High, Week 16 (n=51)23.6
HDL Cholesterol: High, Week 20 (n=52)28.2
HDL Cholesterol: High, Week 24 (n=48)29.6
Triglycerides: Normal, Baseline (n=121)88.4
Triglycerides: Normal, Week 4 (n=116)40.5
Triglycerides: Normal, Week 8 (n=112)82.1
Triglycerides: Normal, Week 12 (n=109)80.7
Triglycerides: Normal, Week 16 (n=106)82.1
Triglycerides: Normal, Week 20 (n=103)75.7
Triglycerides: Normal, Week 24 (n=98)72.4
Triglycerides: Borderline High, Baseline (n=121)8.3
Triglycerides: Borderline High, Week 4 (n=116)28.4
Triglycerides: Borderline High, Week 8 (n=112)8.0
Triglycerides: Borderline High, Week 12 (n=109)8.3
Triglycerides: Borderline High, Week 16 (n=106)8.5
Triglycerides: Borderline High, Week 20 (n=103)9.7
Triglycerides: Borderline High, Week 24 (n=98)16.3
Triglycerides: High, Baseline (n=121)3.3
Triglycerides: High, Week 4 (n=116)25.9
Triglycerides: High, Week 8 (n=112)9.8
Triglycerides: High, Week 12 (n=109)11
Triglycerides: High, Week 16 (n=106)8.5
Triglycerides: High, Week 20 (n=103)14.6
Triglycerides: High, Week 24 (n=98)11.2
Triglycerides: Very High, Baseline (n=121)0.0
Triglycerides: Very High, Week 4 (n=116)5.2
Triglycerides: Very High, Week 8 (n=112)0.0
Triglycerides: Very High, Week 12 (n=109)0.0
Triglycerides: Very High, Week 16 (n=106)0.9
Triglycerides: Very High, Week 20 (n=103)0.0
Triglycerides: Very High, Week 24 (n=98)0.0
SecondaryDisease Activity Score Based on 28-Joint Count (DAS28)

DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR; in millimeters per hour \[mm/hour\]) and global health assessment (participant-rated global assessment of disease activity using 10-mm visual analog assessment \[VAS\]); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 less than or equal to (≤3.2) = low disease activity, DAS28 greater than (\>)3.2 to less than or equal to (≤) 5.1=moderate to high disease activity; DAS28 \>5.1=high disease activity.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · units on a scale
Disease Activity Score Based on 28-Joint Count (DAS28)
units on a scaleTocilizumab 8 mg/kg
Baseline (n=117)6.2 ± 1.5
Week 4 (n=116)4.0 ± 1.6
Week 8 (n=112)3.3 ± 1.4
Week 12 (n=109)2.8 ± 1.4
Week 16 (n=106)2.4 ± 1.4
Week 20 (n=103)2.1 ± 1.2
Week 24 (n=99)2.0 ± 1.3
SecondaryPercentage of Participants by DAS28 Response Category

DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 =low disease activity, DAS28 \>3.2 to ≤5.1=moderate to high disease activity; DAS28 \>5.1=high disease activity.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants by DAS28 Response Category
percentage of participantsTocilizumab 8 mg/kg
DAS28 ≤3.2, Baseline (n=117)0.9
DAS28 ≤3.2, Week 4 (n=116)31.9
DAS28 ≤3.2, Week 8 (n=112)50.9
DAS28 ≤3.2, Week 12 (n=109)67.9
DAS28 ≤3.2, Week 16 (n=106)81.1
DAS28 ≤3.2, Week 20 (n=103)88.3
DAS28 ≤3.2, Week 24 (n=99)83.8
DAS28 >3.2 and ≤5.1, Baseline (n=117)25.6
DAS28 >3.2 and ≤5.1, Week 4 (n=116)43.1
DAS28 >3.2 and ≤5.1, Week 8 (n=112)40.2
DAS28 >3.2 and ≤5.1, Week 12 (n=109)25.7
DAS28 >3.2 and ≤5.1, Week 16 (n=106)13.2
DAS28 >3.2 and ≤5.1, Week 20 (n=103)9.7
DAS28 >3.2 and ≤5.1, Week 24 (n=99)13.1
DAS28 >5.1, Baseline (n=117)73.5
DAS28 >5.1, Week 4 (n=116)25.0
DAS28 >5.1, Week 8 (n=112)8.9
DAS28 >5.1, Week 12 (n=109)6.4
DAS28 >5.1, Week 16 (n=106)5.7
DAS28 >5.1, Week 20 (n=103)1.9
DAS28 >5.1, Week 24 (n=99)3.0
SecondaryPercentage of Participants With a Clinically Meaningful Improvement in Disease Activity

DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. A reduction in DAS28 of at least 1.2 units was considered a clinically meaningful improvement.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinically Meaningful Improvement in Disease Activity
percentage of participantsTocilizumab 8 mg/kg
Baseline0
Week 476.7
Week 891.1
Week 1291.7
Week 1696.2
Week 2098.1
Week 24100
SecondaryTime to Achieve Clinically Meaningful Reduction in DAS28

A clinically meaningful improvement in DAS28 was defined as a reduction of at least 1.2 units. Time to achieving clinically meanigful improvement was calculated as the number of days from the first infusion to the first achievement of reduction of 1.2 units in DAS28.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · days
Time to Achieve Clinically Meaningful Reduction in DAS28
daysTocilizumab 8 mg/kg
Time to Achieve Clinically Meaningful Reduction in DAS2844.7 ± 29.1
SecondaryPercentage of Participants Achieving Remission (DAS28 <2.6)

DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Participants with a DAS28 score \<2.6 were considered to have achieved remission.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission (DAS28 <2.6)
percentage of participantsTocilizumab 8 mg/kg
Baseline (n=117)0.0
Week 4 (n=116)16.4
Week 8 (n=112)30.4
Week 12 (n=109)48.6
Week 16 (n=106)63.2
Week 20 (n=103)73.8
Week 24 (n=99)74.7
SecondaryPercentage of Participants With a Response Assessed Using American College of Rheumatology (ACR) Criteria

The ACR response rates ACR20, ACR50, ACR70 are defined as ≥20%, ≥50%, ≥70% improvement, respectively, in: swollen joint count (SJC) (66 joints) and tender joint count (TJC) (68 joints) and 3 of the following 5 assessments: Patient assessment of pain (VAS); Patient global assessment of disease activity (VAS); Investigator global assessment of disease activity (VAS); and acute phase response (ESR or CRP)

Time frame:
Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Response Assessed Using American College of Rheumatology (ACR) Criteria
percentage of participantsTocilizumab 8 mg/kg
ACR20, Week 4 (n=121)62.0
ACR20, Week 8 (n=112)73.2
ACR20, Week 12 (n=109)78.9
ACR20, Week 16 (n=106)85.8
ACR20, Week 20 (n=103)90.3
ACR20, Week 24 (n=99)87.9
ACR50, Week 4 (n=116)27.6
ACR50, Week 8 (n=112)50.0
ACR50, Week 12 (n=109)63.3
ACR50, Week 16 (n=106)77.4
ACR50, Week 20 (n=103)85.4
ACR50, Week 24 (n=99)80.8
ACR70, Week 4 (n=115)6.9
ACR70, Week 8 (n=112)29.5
ACR70, Week 12 (n=109)32.1
ACR70, Week 16 (n=106)48.1
ACR70, Week 20 (n=103)56.3
ACR70, Week 24 (n=99)61.6
SecondarySwollen and Tender Joint Counts

The following 28 joints were assessed by the physician for swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). The following 28 joints were assessed by the physician for tenderness : metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). The change in SJC and TJC was determined as the difference in values from baseline at each visit.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · joints
Swollen and Tender Joint Counts
jointsTocilizumab 8 mg/kg
SJC Baseline10.8 ± 7.4
SJC Week 44.8 ± 6.0
Change in SJC at Week 46.0 ± 6.5
SJC Week 83.1 ± 4.6
Change in SJC at Week 87.5 ± 6.8
SJC Week 122.8 ± 4.5
Change in SJC at Week 127.8 ± 6.9
SJC Week 161.8 ± 3.4
Change in SJC at Week 168.9 ± 7.4
SJC Week 200.9 ± 1.9
Change in SJC at Week 209.8 ± 7.4
SJC Week 241.0 ± 2.2
Change in SJC at Week 249.9 ± 7.6
TJC Baseline15.4 ± 8.8
TJC Week 49.3 ± 7.7
Change in TJC at Week 46.1 ± 7.6
TJC Week 86.2 ± 5.7
Change in TJC at Week 89.1 ± 7.2
TJC Week 124.7 ± 5.8
Change in TJC at Week 1210.4 ± 7.4
TJC Week 163.3 ± 4.5
Change in TJC at Week 1612.0 ± 7.6
TJC Week 202.5 ± 3.5
Change in TJC at Week 2012.7 ± 7.8
TJC Week 242.3 ± 4.1
Change in TJC at Week 2413.0 ± 8.4
SecondaryHealth Assessment Questionnaire (HAQ)

HAQ was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple-choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The change in HAQ was determined as the difference in values from baseline at each visit.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Health Assessment Questionnaire (HAQ)
score on a scaleTocilizumab 8 mg/kg
Baseline1.97 ± 0.82
Week 41.44 ± 0.83
Change at Week 40.52 ± 0.55
Week 81.02 ± 0.73
Change at Week 80.94 ± 0.72
Week 120.80 ± 0.70
Change at Week 121.14 ± 0.79
Week 160.70 ± 0.77
Change at Week 161.24 ± 0.91
Week 200.56 ± 0.66
Change at Week 201.33 ± 0.86
HAQ Week 240.56 ± 0.69
Change at Week 241.32 ± 0.87
SecondaryPatient Global Assessment of Disease Activity (VAS)

The participant's overall assessment of their current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no disease activity" (symptom free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity" (maximum arthritis disease activity). The change in Patient Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · mm
Patient Global Assessment of Disease Activity (VAS)
mmTocilizumab 8 mg/kg
Baseline64.2 ± 18.6
Week 440.6 ± 20.7
Change at Week 423.6 ± 21.5
Week 828.8 ± 19.8
Change at Week 835.6 ± 22.0
Week 1221.4 ± 18.1
Change at Week 1242.8 ± 23.8
Week 1618.1 ± 19.2
Change at Week 1646.4 ± 25.2
Week 2011.3 ± 12.3
Change at Week 2053.0 ± 22.0
Week 2412.0 ± 15.3
Change at Week 2451.6 ± 25.3
SecondaryPhysician's Global Assessment of Disease Activity (VAS)

The physician's assessment of the participant's current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity". The Physician's Global Assessment of Disease Activity was completed by the Efficacy Assessor who could or could not be a physician. The change in Physician's Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · mm
Physician's Global Assessment of Disease Activity (VAS)
mmTocilizumab 8 mg/kg
Baseline61.8 ± 18.3
Week 437.7 ± 20.5
Change at Week 424.3 ± 20.3
Week 826.7 ± 19.4
Change at Week 835.4 ± 21.7
Week 1220.0 ± 17.3
Change at Week 1241.6 ± 23.5
Week 1616.0 ± 18.8
Change at Week 1646.0 ± 24.6
Week 2010.0 ± 10.9
Change at Week 2051.8 ± 21.0
Week 2410.7 ± 13.2
Change at Week 2450.6 ± 23.3
SecondaryPatient Assessment of of Pain (VAS)

The participant's assessment of their current level of pain was displayed on a 100-mm horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no pain" and the right-hand extreme of the line (100 mm) was described as "unbearable pain". The change in participant's perception of pain was determined as the difference in values from baseline at each visit.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · mm
Patient Assessment of of Pain (VAS)
mmTocilizumab 8 mg/kg
Baseline63.4 ± 18.7
Week 441.4 ± 21.1
Change at Week 421.9 ± 20.7
Week 829.1 ± 21.0
Change at Week 834.5 ± 23.1
Week 1221.4 ± 18.1
Change at Week 1241.7 ± 24.1
Week 1616.3 ± 17.7
Change at Week 1646.6 ± 24.5
Week 2010.6 ± 10.9
Change at Week 2052.3 ± 21.8
Week 2411.3 ± 14.3
Change at Week 2451.5 ± 25.4
SecondaryC-Reactive Protein (CRP)

CRP is an acute phase inflammatory marker. Levels of CRP increase with inflammation. The change in CRP was determined as the difference in values from baseline and at each visit.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · mg/dL
C-Reactive Protein (CRP)
mg/dLTocilizumab 8 mg/kg
Baseline22.9 ± 24.1
Week 46.5 ± 14.8
Change at Week 416.6 ± 27.3
Week 84.9 ± 6.4
Change at Week 817.7 ± 23.1
Week 125.1 ± 9.4
Change at Week 1216.8 ± 24.3
Week 165.2 ± 7.5
Change at Week 1617.2 ± 23.3
Week 206.1 ± 11.6
Change at Week 2016.0 ± 24.1
Week 246.7 ± 8.7
Change at Week 2416.1 ± 24.3
SecondaryErythrocyte Sedimentation Rate (ESR)

ESR indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. The change in ESR was determined as the difference in values from baseline at each visit.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · mm/hr
Erythrocyte Sedimentation Rate (ESR)
mm/hrTocilizumab 8 mg/kg
Baseline31.4 ± 23.3
Week 49.5 ± 11.7
Change at Week 421.8 ± 20.1
Week 88.3 ± 11.6
Change at Week 822.4 ± 20.7
Week 128.6 ± 12.0
Change at Week 1222.9 ± 21.3
Week 168.1 ± 13.0
Change at Week 1623.0 ± 18.9
Week 207.8 ± 11.3
Change at Week 2022.4 ± 19.4
Week 248.2 ± 9.7
Change at Week 2422.2 ± 2.4
PrimaryPercentage of Participants With Adverse Events

Percentage of participants with adverse events (AEs), serious adverse events (SAEs), severe AEs, AEs leading to withdrawal, AEs leading to death, and treatment-related AEs.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsTocilizumab 8 mg/kg
AEs48.8
SAEs10.7
With severe AEs8.3
AEs leading to withdrawals5.8
AEs leading to death0.8
Treatment-related AEs10.7
Treatment-related SAEs4.1
Treatment-related severe AEs5.0

Adverse events

Collected over Adverse events (AE) were recorded from the date of first infusion to the end of study visit at Week 24.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab 8 mg/kg—13/121 (10.7%)59/121 (48.8%)
Most frequent serious events
Most frequent serious events
EventTocilizumab 8 mg/kg
Hepatic cytolysisHepatobiliary disorders3/121
HypertensionVascular disorders2/121
PneumoniaInfections and infestations2/121
NeutropeniaBlood and lymphatic system disorders1/121
MetrorrhagiaReproductive system and breast disorders1/121
Worsening of arthralgiaMusculoskeletal and connective tissue disorders1/121
Necrotising fasciitisInfections and infestations1/121
BronchitisInfections and infestations1/121
Cervical cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/121
Most frequent other events
Showing 10 of 47
Most frequent other events
EventTocilizumab 8 mg/kg
Elevation of the AST/ALT levelsInvestigations22/121
HypercholesterolemiaInvestigations18/121
HypertriglyceridemiaInvestigations16/121
Bilirubin level elevationsInvestigations15/121
NeutropeniaBlood and lymphatic system disorders12/121
ThrombocytopeniaBlood and lymphatic system disorders8/121
LeucopeniaBlood and lymphatic system disorders5/121
AnaemiaBlood and lymphatic system disorders5/121
Increased neutrophil countBlood and lymphatic system disorders4/121
Joint painMusculoskeletal and connective tissue disorders4/121

Baseline characteristics

Intention-to-treat (ITT) population, defined as participants who received at least one dose of tocilizumab (baseline) and for whom data for at least one follow-up variable were available.

Age, Continuous
Age, Continuous(years)Tocilizumab 8 mg/kg
Mean46.3 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab 8 mg/kg
Female96
Male21
08

Study locations

8 sites
  • Casablanca, 20000, Morocco
  • Fés, 30000, Morocco
  • Khouribga, 14000, Morocco
  • Kénitra, 25000, Morocco
  • Marrakech, 40000, Morocco
  • Meknés, 50000, Morocco
  • Rabat, 10000, Morocco
  • Salé, 15045, Morocco
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2012
First posted
Jun 4, 2012
Start
Mar 2010
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Jul 10, 2014
Last update
Jul 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01610791
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 4, 2012
Start date
Mar 2010
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Jul 10, 2014
Last update
Jul 10, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion